Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)
Trial details
- Registry ID
- NCT03881852
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as AXS-12; Reboxetine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Clinical Outcomes in Narcolepsy and Cataplexy: An Evaluation of Reboxetine Treatment (CONCERT)NCT03881852 | AXSM | Phase 2 | Completed | 2019-11-27Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |